Table 3.
Risks for in situ and invasive other female genital cancers in families of any in situ cancer, and risk for any in situ cancers in families of in situ and invasive other female genital cancers.
| Cancer site family member | RR for in situ female genital cancer when family member had in situ cancer | RR for in situ cancer when family member had in situ female genital cancer | RR for female genital cancer when family member had in situ cancer | RR for in situ cancer when family member had female genital cancer | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | RR | 95%CI | Cases | RR | 95%CI | Cases | RR | 95%CI | Cases | RR | 95%CI | |
| Cervix | 347 | 1.79 | 1.60–2.01 | 458 | 1.59 | 1.45–1.74 | 166 | 1.48 | 1.27–1.74 | 475 | 1.19 | 1.09–1.30 |
| Skin, squamous cell | 163 | 1.25 | 1.06–1.46 | 73 | 1.38 | 1.09–1.73 | 86 | 1.01 | 0.81–1.25 | 121 | 1.15 | 0.96–1.38 |
| Male | NR | 45 | 1.69 | 1.26–2.26 | NR | 52 | 1.00 | 0.76–1.31 | ||||
| Female | As above | 28 | 1.06 | 0.73–1.53 | As above | 69 | 1.30 | 1.03–1.65 | ||||
| Upper aerodigestive tract | 8 | 1.73 | 0.86–3.45 | 4 | 1.86 | 0.70–4.95 | 5 | 1.64 | 0.68–3.95 | 3 | 0.75 | 0.24–2.34 |
| Male | NR | 3 | 2.13 | 0.69–6.62 | NR | 3 | 1.16 | 0.37–3.60 | ||||
| Female | As above | 1 | 1.33 | 0.19–9.46 | As above | 0 | — | — | ||||
| Other male genital | 5 | 2.82 | 1.17–6.78 | 6 | 3.79 | 1.70–8.46 | 2 | 1.83 | 0.46–7.34 | 4 | 1.59 | 0.60–4.26 |
| Colorectum | 39 | 0.87 | 0.63–1.19 | 25 | 0.95 | 0.64–1.41 | 27 | 0.92 | 0.63–1.35 | 43 | 0.85 | 0.63–1.15 |
| Male | NR | 14 | 1.69 | 1.26–2.26 | NR | 26 | 0.90 | 0.61–1.32 | ||||
| Female | As above | 11 | 0.98 | 0.55–1.78 | As above | 17 | 0.79 | 0.49–1.27 | ||||
| Ovary | 16 | 1.66 | 1.02–2.71 | 17 | 1.85 | 1.15–2.98 | 5 | 0.81 | 0.34–1.95 | 18 | 1.20 | 0.75–1.90 |
| Melanoma | 31 | 0.90 | 0.63–1.28 | 37 | 1.09 | 0.79–1.50 | 11 | 0.55 | 0.30–1.00 | 55 | 0.96 | 0.74–1.25 |
| Male | NR | 15 | 0.93 | 0.56–1.54 | NR | 32 | 1.14 | 0.81–1.62 | ||||
| Female | As above | 22 | 1.23 | 0.81–1.86 | As above | 23 | 0.79 | 0.52–1.19 | ||||
| Non-Hodgkin lymphoma | 2 | 0.89 | 0.22–3.54 | 2 | 1.39 | 0.35–5.56 | 0 | — | — | 0 | — | — |
| Male | NR | 1 | 1.19 | 0.17–8.45 | 0 | — | — | 0 | — | — | ||
| Female | As above | 1 | 1.67 | 0.24–11.91 | 0 | — | — | 0 | — | — | ||
| All (including female genital) | 668 | 1.48 | 1.36–1.62 | 697 | 1.46 | 1.35–1.57 | 330 | 1.15 | 1.03–1.30 | 839 | 1.13 | 1.05–1.21 |
| Male | NR | 102 | 1.34 | 1.11–1.63 | NR | 153 | 1.08 | 0.92–1.27 | ||||
| Female | As above | 595 | 1.47 | 1.36–1.60 | As above | 686 | 1.14 | 1.05–1.22 | ||||
RR = relative risk, 95%CI = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not include 1.00